Prospective, multicentre trial evaluating FET-PET in Glioblastoma

The FIG trial is investigating how the addition of FET-PET imaging to standard MRI imaging affects radiation target volume delineation and treatment planning for Glioblastoma, as well as determining the accuracy and management impact of FET-PET in distinguishing pseudoprogression from true tumour progression and / or tumour recurrence.

Primary Sponsor

Trans Tasman Radiation Oncology Group (TROG)

Collaborating Groups

COGNO, ARTnet, ONJCRI

Participating Centres

Accrual Target

210

Current Accrual

Expected Date of Accrual

31 December 2024

Trial Chairperson

Prof Andrew Scott, Olivia Newton-John Cancer Research Institute (ONJCRI) / The Austin Health, VIC, Australia

A/Prof Eng-Siew Koh, Liverpool Hospital, NSW, Australia

Trial Contact

FIG@trog.com.au

Clinical Trial Registration

Related Post

Tour de Cure grants for TROG Cancer Research trials
9 January, 2025

Tour de Cure grants support two valuable TROG trials

9 January 2025: Two important TROG Cancer Research trials

7 January, 2025

GenesisCare Foundation $300,000 donation to support TROG work

7 January 2025: TROG Cancer Research is advancing vital